- Trials with a EudraCT protocol (53)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
53 result(s) found for: DEXA scan.
Displaying page 3 of 3.
EudraCT Number: 2014-002039-32 | Sponsor Protocol Number: PlenadrEMA/1.1/2014 | Start Date*: 2014-09-02 | |||||||||||
Sponsor Name:Rigshospitalet, Copenhagen University Hospital | |||||||||||||
Full Title: PlenadrEMA study - Effect of modified-release compared to conventional hydrocortisone on fatigue, measured by Ecological Momentary Assessments; a pilot study to assess feasibility, responsiveness o... | |||||||||||||
Medical condition: Secondary adrenal insufficiency due to hypopituitarism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003743-10 | Sponsor Protocol Number: 2016-779 | Start Date*: 2017-02-06 |
Sponsor Name:Herlev og Gentofte Hospital | ||
Full Title: Effects of SGLT-2 Inhibitor on Myocardial Perfusion, Function and Metabolism in Type 2 DM Patients at high cardiovascular risk: The SIMPle Randomized Clinical Trial | ||
Medical condition: Type 2 diabetes and cardiovascular risk | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-001946-32 | Sponsor Protocol Number: ARRAY-162-115 | Start Date*: 2021-12-07 | |||||||||||
Sponsor Name:Array BioPharma Inc. | |||||||||||||
Full Title: A Multicenter, Open-label Phase Ib Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients with Unresectable or Metastatic BRAF V600-mutant Melanoma P/071/2018 | |||||||||||||
Medical condition: Unresectable or metastatic BRAF V600-mutant melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006184-19 | Sponsor Protocol Number: SPI-62-CL-2001 | Start Date*: 2022-06-22 | |||||||||||
Sponsor Name:Sparrow Pharmaceuticals, Inc. | |||||||||||||
Full Title: SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing’s Syndrome | |||||||||||||
Medical condition: Cushing’s Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005949-16 | Sponsor Protocol Number: 202000894 | Start Date*: 2021-10-25 | ||||||||||||||||||||||||||
Sponsor Name:University Medical Center Groningen | ||||||||||||||||||||||||||||
Full Title: A GnRH Agonist IN pre-menopausal women STudy to treat severe Polycystic Liver Disease | ||||||||||||||||||||||||||||
Medical condition: Severe polycystic liver disease in female patients | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||||||||||||
Trial protocol: NL (Trial now transitioned) DE (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-010827-23 | Sponsor Protocol Number: RENVEL | Start Date*: 2010-02-02 | |||||||||||
Sponsor Name:Fundación PETHEMA | |||||||||||||
Full Title: Estudio nacuinal, multicéntrico, abierto, de tratamiento de inducción con VELCADE y Dexametasona en pacientes con mieloma múltiple e insuficiencia renal no tratados previamente | |||||||||||||
Medical condition: Mieloma Múltiple e insuficiencia renal no tratados previamente | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006752-14 | Sponsor Protocol Number: DualActionWeightLossinIIH1 | Start Date*: 2022-08-23 | |||||||||||
Sponsor Name:Rigshospitalet, Neurologisk afdeling | |||||||||||||
Full Title: Glucagone Like Peptide-1 Receptor (GLP-1R) Analogue Assisted Rapid Weight Loss Program as treatment of Idiopathic Intracranial Hypertension | |||||||||||||
Medical condition: Idiopathic Intracranial Hypertension (IIH) is a disease in which the intracranial pressure is pathologically elevated. This can cause blindness, chronic, severe headache, and cognitive dysfunction.... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005760-42 | Sponsor Protocol Number: MBGS205 | Start Date*: 2016-05-25 | |||||||||||
Sponsor Name:Mereo BioPharma 2 Limited | |||||||||||||
Full Title: A Phase IIb multicentre, double-blind, dose-ranging, randomised, placebo-controlled study evaluating safety and efficacy of BGS649 in male obese subjects with hypogonadotropic hypogonadism | |||||||||||||
Medical condition: Hypogonadotropic hypogonadism (HH) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002646-38 | Sponsor Protocol Number: TMC278-TiDP6-C209 | Start Date*: 2008-07-24 | |||||||||||
Sponsor Name:Tibotec Pharmaceuticals Limited | |||||||||||||
Full Title: A Phase III, randomized, double-blind trial of TMC278 75 mg q.d. versus efavirenz 600 mg q.d. in combination with a fixed background regimen consisting of tenofovir disoproxil fumarate and emtricit... | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) AT (Completed) FR (Completed) DK (Completed) ES (Completed) GB (Completed) PT (Completed) SE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000816-24 | Sponsor Protocol Number: FRAN-03-001 | Start Date*: 2004-10-28 | |||||||||||
Sponsor Name:Abbott France | |||||||||||||
Full Title: A Pilot, Open-Label, Randomized, Comparative Study of the Antiviral Efficacy of Lopinavir/Ritonavir Single-Drug Regimen versus Lopinavir/Ritonavir in Combination with Lamivudine/Zidovudine in Antir... | |||||||||||||
Medical condition: HIV-1 Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002647-25 | Sponsor Protocol Number: TMC278-TiDP6-C215 | Start Date*: 2007-12-18 | |||||||||||
Sponsor Name:Tibotec Pharmaceuticals | |||||||||||||
Full Title: A Phase III, randomized, double-blind trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in combination with a background regimen containing 2 nucleoside/nucleotide reverse transcriptase inhib... | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) FR (Completed) PT (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001552-19 | Sponsor Protocol Number: TOPMATEPY4067 | Start Date*: 2014-12-16 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Randomized, Active-Controlled, Open-Label, Flexible-Dose Study to Assess the Safety and Tolerability of Topiramate as Monotherapy Compared with Levetiracetam as Monotherapy in Pediatric Subjects ... | |||||||||||||
Medical condition: New-onset or recent-onset epilepsy. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) IT (Completed) HU (Completed) BE (Completed) DE (Completed) GB (Completed) FR (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004679-36 | Sponsor Protocol Number: 05 2015-001 | Start Date*: 2006-12-13 | |||||||||||
Sponsor Name:Laboratoire HRA Pharma | |||||||||||||
Full Title: Prospective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion. | |||||||||||||
Medical condition: Treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
